7 research outputs found
Can pneumococcal meningitis surveillance be used to assess the impact of pneumococcal conjugate vaccine on total invasive pneumococcal disease? A case-study from South Africa, 2005–2016
INTRODUCTION : South Africa introduced seven-valent pneumococcal conjugate vaccine (PCV7) in 2009 and PCV13 in 2011. We aimed to compare the estimated impact of PCV on pneumococcal meningitis (PM) to impact of PCV on total invasive pneumococcal disease (tIPD) based on risk reduction after PCV introduction.
METHODS : We conducted national, laboratory-based surveillance for tIPD during 2005–2016. We estimated and compared rates of PCV13 and non-PCV13 serotype disease among tIPD and PM in individuals aged <5 years and ≥5 years, and compared these rates between the 2005–2008 pre-PCV introduction period and two time points after PCV introduction, 2012 and 2016.
RESULTS : We enrolled 45,853 tIPD cases; 17,251 (38%) were PM. By 2016, IPD caused by all serotypes decreased 55% (95%CI −57% to −53%) for tIPD, and 54% for PM (95%CI −58% to −51%), 0.7% difference between estimates (p = 0.7). No significant differences were observed between PCV7-serotype disease reduction in tIPD and PM in both age groups or the additional 6 serotypes included in PCV13 in <5 year olds in 2012 and 2016. In 2012 there was a significant difference between increases in non-PCV13 serotype disease in those ≥5 years for tIPD and PM (32% greater increase in PM, p < 0.001), but this difference was absent by 2016. There was a significant difference between the estimated decrease in additional PCV13 type disease in 2016 between tIPD and PM for those aged ≥5 years (28% greater reduction in PM, p = 0.008).
CONCLUSION : PM showed similar reductions to tIPD seven years after PCV introduction in vaccine serotype disease in those <5 years, and increases in non-vaccine serotype disease in all ages.The National Institute for Communicable Diseases a division of the National Health Laboratory Service, South Africa; the United States Agency for International Development’s Antimicrobial Resistance Initiative, United States of America, transferred via a cooperative agreement [U60/CCU022088] from the United States Centers for Disease Control and Prevention, United States if Ameriva; and the United States Centers for Disease Control and Prevention [U62/CCU022901], United States of America.http://www.elsevier.com/locate/vaccine2020-09-10hj2019School of Health Systems and Public Health (SHSPH
Part IV. Human infections and antibiotic resistance
South Africa has a high burden of infectious diseases, including
a large portion that are of bacterial origin. This section reviews
the national burden of disease and levels of antibiotic resistance
in common bacterial infections in the human population. The
consequences of resistance on clinical outcomes, through either
treatment failures or the development of more virulent infections, are
largely unknown. The full impact of antibiotic resistance on health in
South Africa therefore remains to be assessed.http://www.samj.org.z
Systemic shigellosis in South Africa
BACKGROUND: Systemic disease due to shigellae is associated with human immunodeficiency virus (HIV),
malnutrition, and other immunosuppressed states. We examined the clinical and microbiologic characteristics of
systemic shigellosis in South Africa, where rates of HIV infection are high.
METHODS: From 2003 to 2009, 429 cases of invasive shigellosis were identified through national laboratory-based
surveillance. At selected sites, additional information was captured on HIV serostatus and outcome. Isolates were
serotyped and antimicrobial susceptibility testing performed.
RESULTS: Most cases of systemic shigellosis were diagnosed on blood culture (408 of 429 cases; 95%). HIV
prevalence was 67% (80 of 120 cases), highest in patients aged 5–54 years, and higher among females (55 of 70 cases;
79%) compared with males (25 of 48 cases; 52%; P 5 .002). HIV-infected people were 4.1 times more likely to die
than HIV-uninfected cases (case-fatality ratio, 29 of 78 HIV-infected people [37%] vs 5 of 40 HIV-uninfected people
[13%]; P 5 .008; 95% confidence interval [CI], 1.5–11.8). The commonest serotype was Shigella flexneri 2a (89 of
292 serotypes [30.5%]). Pentavalent resistance occurred in 120 of 292 isolates (41.1%). There was no difference in
multidrug resistance between HIV-infected patients (33 of 71 [46%]) and uninfected patients (12 of 33 [36%]; 95%
CI, .65–3.55).
CONCLUSIONS: Systemic shigellosis is associated with HIV-infected patients, primarily in older girls and women,
potentially due to the burden of caring for sick children in the home; interventions need to be targeted here. Death
rates are higher in HIV-infected versus uninfected individuals.The US Agency
for International Development’s Antimicrobial Resistance Initiative,
transferred via a cooperative agreement (grant U60/CCU022088) from the
Centers for Disease Control and Prevention (CDC), Atlanta, Georgia. For
2007–2009, it was supported by the Departments of Health and Human
Services (HHS) CDC, the National Center for HIV/AIDS, Viral Hepatitis,
STD, and TB Prevention (NCHHSTP), the Global AIDS Program (GAP)
Cooperative Agreement (U62/PSO022901).
P. C.-G. and S. M. are funded through grant U60/CCU022088.http://cid.oxfordjournals.org
[unknown]
原著和名: [記載なし]科名: マメ科 = Leguminosae採集地: タイ バンコク市内 (タイ国 バンコク市内)採集日: 1984/10/10採集者: 萩庭丈壽整理番号: JH050727国立科学博物館整理番号: TNS-VS-999700備考: 栽培
Meningococcal serogroup Y lpxL1 variants from South Africa are associated with clonal complex 23 among young adults
To determine the genotypes of serogroup Y meningococcus (MenY), and to determine the prevalence of and identify factors associated with MenY lpxL1 variants. Isolates, collected from 2003 to 2007 through national surveillance for invasive meningococcal disease, were characterized by multilocus sequence typing and screened for interleukin-6 induction. LpxL1 genes were sequenced from low IL-6 inducers. MenY represented 13% (n = 219/1702) of meningococcal disease. Clonal complex (cc) 175, ST-23/Cluster A3 (cc23), cc11 and cc167 accounted for 82% (176/214), 11% (24/214), 3% (6/214) and 3% (7/214) respectively. Low cytokine induction was evident in 15% (32/218). Cc23 isolates (24/24) had an lpxL1 mutation, while among the remaining isolates the proportion of lpxL1 variants was 4% (8/189, p < 0.001), and these were all cc175. Compared to wild type isolates, lpxL1 variants were associated with patients aged 5-14 years [unadjusted OR (95% CI): 4.3 (1.5-12)] or 15-24 years [unadjusted OR (95% CI): 9.1 (2.8-29)] compared to children <5 years; and were more likely have been isolated from CSF than blood [unadjusted OR (95% CI): 3.5 (1-11.9)]. On multivariable analysis, age remained significant [adjusted OR (95% CI), 5-14 years: 4.2 (1.5-12); 15-24 years: 8.9 (2.7-29)]. LpxL1 variants were associated with cc23 among young adult